UBI is a privay held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases

 

UBI is a privay held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.

Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.

UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

Catalog # 600441, UBI^® HIV-1/2 EIA kit, 192 tests 
Catalog # 600061, UBI^® HCV EIA kit, 192 tests
Catalog # 600318, UBI^® HCV EIA kit, 576 tests 
PUBLICATION ON UBI^® FMDV NS ELISA （SWINE）